Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Metrics to compare | ORKA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORKAPeersSector | |
---|---|---|---|---|
P/E Ratio | −7.0x | −3.5x | −0.5x | |
PEG Ratio | - | −0.06 | 0.00 | |
Price/Book | 1.6x | 2.1x | 2.6x | |
Price / LTM Sales | - | 10.0x | 3.3x | |
Upside (Analyst Target) | 171.4% | 184.3% | 42.8% | |
Fair Value Upside | Unlock | −0.2% | 6.5% | Unlock |